Glycemic profile variability: An independent risk factor for diabetic neuropathy in patients with type 2 diabetes
Primary Care Diabetes · 2023-02 · 17 (1) · 38-42
DOI: 10.1016/j.pcd.2022.11.011 ↗Kurz gefasst
Fachartikel in der Zeitschrift Primary Care Diabetes, 2023-02. Verfasst von Mohammad Dehghani Firouzabadi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Endocrinology and Metabolism Research Center (EMRC), Vali-Asr Hospital, Tehran University of Medical Sciences, Tehran, Iran; Department of Radiology …. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Diabetic Neuropathies. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 34 Literaturangaben.
Themen: Diabetes mellitus
Abstract (Originalsprache)
BACKGROUND: Impaired glycemic control is a potential predictor for macro- and microvascular complications of diabetes, which could be recognized by glycemic variability. The aim of this 10-year prospective cohort study presented here is to gain a better understanding of the correlation between GV and diabetic peripheral neuropathy (DPN) as one of the most common complications of T2DM. METHODS: Since February 2010, 1152 adult patients with T2DM have been followed-up. Baseline features, anthropometric measurements, and laboratory findings were collected and documented during ten years. The association between DPN incidence and glycemic profile variability was evaluated using cox regression analysis. The coefficient of variation of glycemic indices within subjects was calculated and compared using an independent sample t-test. RESULTS: Individuals who developed neuropathy had significantly higher mean levels of glycemic indices (HbA1c, FBS, and 2hpp), urinary albumin excretion, mean creatinine levels, and a longer duration of diabetes. A significant positive correlation between incidence of DPN and glycemic profile variability (cv-FBS10 %, cv-FBS20 %, cv-2hpp20 %, cv-HbA1c5 % and cv-HbA1c10 %) was revealed. Results also showed that higher variability of FBS was associated with the higher risk of neuropathy incidence (HR: 12.29, p-value: 0.045), which indicates that glycemic profile variability is an independent risk factor for DPN in patients with T2DM. CONCLUSION: Variability of glycemic profiles from a visit to visit, regardless of sustained hyperglycemia, was indeed a significant risk factor for DPN in diabetic type 2 patients. CV-FBS was the most critical glycemic variability indices for DPN development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Endocrinology and Metabolism Research Center (EMRC), Vali-Asr Hospital, Tehran University of Medical Sciences, Tehran, Iran; Department of Radiology and Imaging Sciences, Clinical Center, National Institutes of Health,…
- Endocrinology and Metabolism Research Center (EMRC), Vali-Asr Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Zitieren
APA
Firouzabadi, M. D., Poopak, A., Sheikhy, A., Samimi, S., Nakhaei, P., Firouzabadi, F. D., Moosaie, F., Rabizadeh, S., Nakhjavani, M., & Esteghamati, A. (2023). Glycemic profile variability: An independent risk factor for diabetic neuropathy in patients with type 2 diabetes. Primary Care Diabetes, 17(1), 38-42. https://doi.org/10.1016/j.pcd.2022.11.011
Vancouver
Firouzabadi MD, Poopak A, Sheikhy A, Samimi S, Nakhaei P, Firouzabadi FD, et al. Glycemic profile variability: An independent risk factor for diabetic neuropathy in patients with type 2 diabetes. Primary Care Diabetes. 2023;17(1):38-42. doi:10.1016/j.pcd.2022.11.011
BibTeX
@article{Firouzabadi2023,
author = {Firouzabadi, Mohammad Dehghani and Poopak, Amirhossein and Sheikhy, Ali and Samimi, Sahar and Nakhaei, Pooria and Firouzabadi, Fatmeh Dehghani and Moosaie, Fatemeh and Rabizadeh, Soghra and Nakhjavani, Manouchehr and Esteghamati, Alireza},
title = {Glycemic profile variability: An independent risk factor for diabetic neuropathy in patients with type 2 diabetes},
journal = {Primary Care Diabetes},
year = {2023},
volume = {17},
number = {1},
pages = {38--42},
doi = {10.1016/j.pcd.2022.11.011}
}
EUVIMED